GlassScriptPhysician profile
Nima M Mazhari
NPI 1710092309
$1,681.09
in general payments reported to CMS, 2019-2025
20 companies · $697 in 2025
The $697 reported for 2025 was more than what 85% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $29.03 · 2021: $76.77 · 2022: $121 · 2023: $275 · 2024: $482 · 2025: $697.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,454.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,453.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tarsus Pharmaceuticals, INC. | $301.39 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $213.21 | 2022-2025 | |
| Alcon Vision LLC | $188.54 | 2019-2025 | Simbrinza, Eysuvis |
| Amgen INC. | $156.22 | 2024-2025 | Tepezza |
| Bausch & Lomb Americas INC. | $153.32 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Dompe US, INC. | $116.77 | 2024-2025 | Oxervate |
| Oyster Point Pharma, INC. | $105.64 | 2023-2025 | Tyrvaya, Ryzumvi |
| Rayner Intraocular Lenses Limited | $84.84 | 2022-2024 | Rayone Emv, Rayone Spheric, Rayone Aspheric |
| Horizon Therapeutics Plc | $83.42 | 2023 | Tepezza |
| Coopervision INC. | $79.88 | 2023 | Myday Contact Lens |
| Sight Sciences, INC. | $33.26 | 2025 | Omni Surgical System, Sion Surgical Instrument |
| Biotissue Holdings INC. | $32.71 | 2022-2023 | |
| Rxsight INC | $24.61 | 2025 | Rxsight Injector Handpiece, Rxsight Light Delivery Device (Ldd), Rxsight Injector Cartridge |
| Kala Pharmaceuticals, INC. | $17.65 | 2022 | |
| Omeros Corporation | $17.34 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $16.07 | 2021 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $15.77 | 2021 | |
| Aerie Pharmaceuticals, INC. | $14.42 | 2021 | |
| Merz Pharmaceuticals, LLC | $13.17 | 2021 | |
| Genentech USA, INC. | $12.86 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nima Mazhari listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.